ArticleClinical and molecular hepatology2025
GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma.
Article in Clinical and molecular hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Integrated Transcriptomic Analyses Identify Four Prognosis-Associated Genes in Hepatocellular Carcinoma.International journal of molecular sciences · 2026Article
- SNX8 regulates BMPR2-mediated SMAD5 proteostasis to drive epithelial-mesenchymal transition in hepatocellular carcinoma.Journal of translational medicine · 2026Article
- Reply to correspondence on "Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography".Clinical and molecular hepatology · 2026Article
- GULP1, a multifaceted diagnostic biomarker and potential therapeutic target in hepatocellular carcinoma: Editorial on "GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma".Clinical and molecular hepatology · 2026Article
- Identifying Immunological Biomarkers for Major Depressive Disorder: Insights From Machine Learning, Single-Nucleus Bioinformatics, and Experimental Validation.BioMed research international · 2026Article
- Letter to the editor on "GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma".Clinical and molecular hepatology · 2026Article
- Unveiling GULP1 as a hepatocyte-specific role for recurrence: Editorial on "GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma".Clinical and molecular hepatology · 2026Article
- Correspondence to editorial on "GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma".Clinical and molecular hepatology · 2026Article
- GULP1: New hope for hepatocellular carcinoma: Reply to correspondence on "GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma".Clinical and molecular hepatology · 2026Article
- Serum Extracellular Vesicle-Associated GULP1 Is a Key Indicator of Hepatocellular Carcinoma.Oncology research · 2026Article
- Correspondence to letter to the editor on "GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma".Clinical and molecular hepatology · 2026Article
- Systematic analysis of the expression profiles and prognostic values of the FAM72 family in liver cancer.Biochemistry and biophysics reports · 2025Article
- Serum Proteomic Profile Based on the TGF-β Pathway Stratifies Risk of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- The evolving landscape of biomarkers for systemic therapy in advanced hepatocellular carcinoma.Biomarker research · 2025Review
- Advances in research regarding epithelial-mesenchymal transition and prostate cancer.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND/
aimsHepatocellular carcinoma (HCC) is characterized by high recurrence and mortality, necessitating the identification of reliable biomarkers. In this study, we aimed to identify the predictive gene signatures for HCC recurrence and evaluate the efficiency of GULP PTB domain-containing engulfment adaptor 1 (GULP1) as a predictive and diagnostic marker and therapeutic target for HCC.
methodsWe analyzed genomic datasets from The Cancer Genome Atlas and Gene Expression Omnibus databases via least absolute shrinkage and selection operator Cox regression and 10-fold cross-validation, leading to the development of a 15-gene risk score model, which was validated using three independent datasets. Serum GULP1 and α-fetoprotein levels were assessed to determine the diagnostic accuracy of the model. Using clinical cohorts and patient sera, GULP1 roles were examined, and functional assays in vitro and in vivo were used to evaluate its effects on cell growth, epithelial-mesenchymal transition (EMT), ADP-ribosylation factor 6 (ARF6) activation, and β-catenin signaling.
resultsOur newly developed risk-score model accurately predicted recurrent HCC in all datasets. Among the 15 genes in the risk score model, GULP1 was overexpressed in patients with HCC and independently predicted HCC recurrence. Its expression modulation influenced cell growth and EMT, with observed effects on ARF6 activation and β-catenin signaling pathways.
conclusionGULP1 is a crucial biomarker for HCC, serving as a non-invasive diagnostic and predictive tool. It also plays key roles in HCC progression. Our findings highlight the potential use of GULP1 in treatment strategies targeting EMT and HCC recurrence to improve the personalized care and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.